National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

lonaprisan
An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:progesterone receptor antagonist ZK 230211
Code name:ZK 230211
Chemical structure names:
  • 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17-hydroxy-19-nor-17α-pregna-4,9- dien-3-one
  • 19-norpregna-4,9-dien-3-one, 11-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17- hydroxy-, (11β,17α)-



Previous:lobradimil, Lodine, lometrexol, lomustine, lonafarnib
Next:loperamide hydrochloride, lopinavir, lorazepam, Lotrimin, lovastatin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov